San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...

Get unlimited access to ad-free articles and exclusive content. Hemispherx and Chronix Plan Studies to Validate Technology as a Potential Diagnostic Test for CFS SAN JOSE, Calif., March 3, 2011 (GLOBE ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease ...

Enabled Chronix to Complete Proof-of-Concept Studies Confirming Its Serum DNA Biomarkers Can Accurately Detect Early Stage Cancer and to File Two Key Patents SAN JOSE, Calif.--(BUSINESS WIRE)-- ...

Chronix Biomedical has announced that it will launch a new disease detection and monitoring service for cancer researchers at the upcoming 2010 ASCO Annual Meeting. The “For Investigational Use Only” ...

Oncocyte’s technologies may provide more precision to the selection of appropriate immune therapies and monitoring for treatment response in real time allowing physicians to personalize treatment more ...

SAN JOSE, Calif.--(BUSINESS WIRE)--Chronix Biomedical today announced that it is partnering with the University of Calgary to develop a commercial version of its serum DNA-based blood test for the ...

San Jose, California, June 23, 2009 – Chronix Biomedical today reported that a new study in a peer-reviewed journal further confirms the potential diagnostic and prognostic utility of using ...

IRVINE, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points ...

Chronix Biomedical, a diagnostic test development company that has operated mostly in secret since its 2000 inception, has finally come out of its shell — publishing information on its product in ...